Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Aging does not impact safety and efficacy of biologic or targeted synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Abstract Background The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results This retrospective study included 52 RA patients. At baseline elderly pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Yasemin Tombak, Ajda Bal, Emel Eksioglu, Nihan Abidin, Ozgur Zeliha Karaahmet, Deniz Dulgeroglu
Format: Article
Language:English
Published: SpringerOpen 2025-06-01
Series:Egyptian Rheumatology and Rehabilitation
Subjects:
bDMARDs
Elderly
EULAR
HAQ
Rheumatoid arthritis
Safety of DMARDs
Online Access:https://doi.org/10.1186/s43166-025-00336-2
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The study compared biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) efficacy and safety in elderly rheumatoid arthritis (RA) patients over a period of 1 year. Results This retrospective study included 52 RA patients. At baseline elderly patients had longer disease duration, more comorbidities and extraarticular involvement, and previously used conventional synthetic (cs) DMARDs (p < 0.05). A statistically significant change from baseline was observed in the 6th and 12th months regarding Disease Activity Score (DAS-28) and the Health Assessment Questionnaire (HAQ) scores were observed in both groups following treatment with bDMARDs/tsDMARD (p < 0.000). These changes in DAS-28 and HAQ scores were similar in both groups and showed no statistical difference between groups (p = 0.974 and p = 0.578 respectively). Also, no differences were observed between the groups with respect to the percentage of good, moderate or non-responders according to European Alliance of Associations for Rheumatology response criteria. Similarly, no differences were found between groups regarding severe adverse events, drug discontinuation or switch rates. Conclusion The efficacy and adverse effects of bDMARDs/tsDMARD were similar in elderly and younger RA patients. Both bDMARDs and tsDMARD are efficacious and safe for use in elderly RA patients.
ISSN:2090-3235

Similar Items